

### PACKAGING

Ref.: 101-0548	Cont.: 1 x 45 / 1 x 15 mL
----------------	---------------------------

Store 2 - 8° C.

### CLINICAL SIGNIFICANCE<sup>1</sup>

The C apolipoproteins (C-I, C-II and C-III) are surface components of chylomicrons, VLDL and HDL. It appears that the liver is the major site of synthesis of the apo C proteins, with the intestine contributing a minor portion. Apo C-II is present in plasma at a concentration of nearly 4 mg/dL, and its prime metabolic function appears to be associated with its ability to act as a cofactor in activating lipoprotein lipase (LPL), enzyme that hydrolyses the triglycerides in the lipoprotein, liberating fatty acids.

Deficiency or defective apo C-II, reduces the activity of the LPL enzyme, impairs chylomicrons catabolism, and increases plasma triglycerides (500 – 1000 mg/dL). Those affected by this disorder have less than 10% of normal concentration of apo C-II, the minimum amount needed for normal LPL activity.

Homozygous hereditary deficiency of apo C-II leads to a hyperchylomicronemic syndrome very similar to hereditary LPL deficiency. The heterozygous state for one mutant apo C-II allele, when associated with apo E-IV, also is associated with hypertriglyceridemia.

### PRINCIPLE OF THE METHOD

Turbidimetric test for the measurement of apolipoprotein C-II in human serum or plasma.

Anti- Apo C-II antibodies when mixed with samples containing Apo C-II, form insoluble complexes. These complexes cause an absorbance change, dependent upon the Apo C-II concentration of the patient sample, that can be quantified by comparison from a calibrator of known Apo C-II concentration.

### REAGENTS

<b>Diluent (R1)</b>	Tris buffer 100 mmol/L, PEG 4000, pH 8.5. Sodium azide 0.95 g/L.
<b>Antibody (R2)</b>	Goat serum, anti-human Apo C-II, tris 100 mmol/L, pH 7.2. Sodium azide 0.95 g/L.
<b>Optional</b>	APO CAL ref: 101-0499

### CALIBRATION

The assay and the value of the calibrator concentration have been standardized against an Internal Reference Material. It is recommended the use of the APO CAL Calibrator for calibration.

### PREPARATION

**Reagents:** Ready to use.

### STORAGE AND STABILITY

All the components of the kit are stable until the expiration date on the label when stored tightly closed at 2 - 8° C and contaminations are prevented during their use. Do not use reagents over the expiration date.

**Reagent deterioration:** The presence of particles and turbidity.

Do not freeze; frozen Antibody or Diluent could change the functionality of the test.

### ADDITIONAL EQUIPMENT

- Thermostatic bath at 37° C.
- Spectrophotometer or photometer thermostatable at 37° C with a 340 nm filter.

### SAMPLES

Fresh serum or plasma. EDTA or heparin should be used as anticoagulant. Stable 2 weeks at 2 - 8° C or 3 months at -20° C.

The samples with presence of fibrin should be centrifuged before testing.

Do not use highly hemolyzed or lipemic samples.

### PROCEDURE

**Notes: Chronolab has instruction sheets for several automatic analyzers. Instructions for many of them are available on request.**

Linearity depends on the calibrator concentration.

Clinical diagnosis should not be made on findings of a single test result, but should integrate both clinical and laboratory data.

1. Bring the reagents and the photometer (cuvette holder) to 37° C.
2. Assay conditions:

Wavelength : 340 nm  
Temperature : 37° C  
Cuvette lighth path : 1cm

3. Adjust the instrument to zero with distilled water.

4. Pipette into a cuvette:

Reagent R1 (µL)	750
Sample or Calibrator (µL)	25

5. Mix and read the absorbance (A<sub>1</sub>) after the sample addition.
6. Immediately, pipette into de cuvette:

Reagent R2 (µL)	250
-----------------	-----

7. Mix and read the absorbance (A<sub>2</sub>) of calibrators and sample exactly 5 minutes after the R2 addition.

### CALCULATIONS

$$\frac{(A_2 - A_1)_{\text{sample}}}{(A_2 - A_1)_{\text{calibrator}}} \times \text{Calibrator concentration} = \text{mg/dL Apo C-II}$$

### QUALITY CONTROL

Control sera are recommended to monitor the performance of manual and automated assay procedures. Chronolab Apolipoprotein Control (Ref.: 101-0503) is available. Each laboratory should establish its own Quality Control scheme and corrective actions if controls do not meet the acceptable tolerances.

### REFERENCE VALUES<sup>5</sup>

Between 1.6 – 4.2 mg/dL.

Each laboratory should establish its own reference range.

### PERFORMANCE CHARACTERISTICS

**1. Linearity:** Up to 10 mg/dL (Note 1), under the described assay conditions. Samples with higher concentrations, should be diluted 1/5 in NaCl (9 g/L) and retested again. The linearity limit depends on the sample / reagent ratio. It will be higher by decreasing the sample volume, although the sensitivity of the test will be proportionally decreased.

**2. Detection Limit:** Values less than 0.4 mg/dL give non-reproducible results.

**3. Prozone effect:** No prozone effect was detected upon 28 mg/dL

**4.Sensitivity:**  $\Delta$  23.5 mA / mg/dL (4.8 mg/dL).

**5.Precision:**

Mean (mg/dL)	Intra-assay (n=10)			Inter-assay (n=5)	
	2.6	3.7	8.1	2.6	3.2
SD	0.08	0.05	0.07	0.04	0.03
CV	2.24	1.39	0.92	1.7	0.9

**6. Accuracy:** Results obtained using this reagent (y) were compared to those obtained with single radial immuno diffusion (SRDI) method. 50 samples ranging from 0.5 to 6 mg/dL of Apo C II were assayed. The correlation coefficient (r) was 0.976 and the regression equation  $y = 1.040 x - 0.12$ .

The results of the performance characteristics depend on the used analyzer.

#### **INTERFERENCES**

Hemoglobin (up to 1000 mg/L), bilirubin (up to 40 mg/dL), and lipemia (up to 20 g/L), do not interfere. Other substances may interfere<sup>6,7</sup>.

#### **BIBLIOGRAPHY**

1. Clinical Guide to Laboratory Tests, Edited by NW Tietz W B Saunders Co., Philadelphia, 483, 1983.
2. Rifai N. Arch Pathol Lab Med 1986; 110: 694-701.
3. Norum RA et al. Precociuos Coronary Disease 1980; 306(25): 1513-1519.
4. Freedman DS et al. N Eng J Med 1986; 315: 721-726.
5. Sakurabayashi I et al. Clin Chim Acta 2001: 312: 87-59.
6. Young DS. Effects of disease on clinical laboratory tests, 3th ed. AACC Pres, 1997.
7. Friedman and Young. Effects of disease on clinical laboratory tests, 3tn ed. AACC Pres, 1997.